Attana in Swedish Life Sciences

Swedes are well known to be innovative and building successful global companies and international brands. In Swedish Life Sciences many of the Swedish companies representing the entire health care spectrum are compiled and presented, there among Attana AB.

The Life Science segment in Sweden is strong with cutting-edge technology, highly educated employees and companies representing the entire health care spectrum – from small start-up companies to universities and big industries, working in the entire range from biotech to medical technology, pharmaceuticals and health care services. In Swedish Life Sciences many of these companies are compiled and presented, there among Attana AB

"Swedish Life Sciences is published in conventional and electronic form. As a beautifully produced hardback book, copies are distributed free of charge throughout the world, and are available at a number of important trade fairs and conferences related to the industry. Additional copies are available on request from Horn Publishing, which also publishes similar books on a range of business sectors and industries in a growing number of countries. When ordering additional copies of the books please explain why you want them and what you plan to do with them".

Fast track to drugability - gain Time-to-Market

Success in clinical trials is dependent on correct information about the drug candidate and target interaction. Failure, on the other hand, is often due to a lack of relevant information in the selection process. By improved selection of drug candidates during the pre-clinical phase the success rate of clinical trials will increase. The Attana Cell 200 biosensor has the unique ability to provide biologically relevant information through measurement of molecular interactions directly in complex conditions such as sera or to human cells. By delivering biologically relevant information at an early stage in the drug discovery process, the Attana Cell 200 minimizes risks and costs and increases success rate during clinical trials.

See the full Attana presentation p. 87 in Swedish Life Sciences, published in October 2012.